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hepatic encephalopathy (HE) and HE-related hospitalizations in a 6-month, randomized,
controlled trial (RCT). We performed a phase 3, open-label maintenance study to assess the
safety and rate of hospitalization with long-term rifaximin use.METHODS: We conducted a 24-month, open-label maintenance study of rifaximin (550 mg, twice daily) in
patients with HEwho participated in the previous RCT of rifaximin or new patients enrolled from
March 2007 to December 2010. Safety was assessed (adverse events, clinical laboratory pa-
rameters) for the integrated population of all patients, who were given rifaximin 550 mg twice
daily (all-rifaximin population, N [ 392). Safety and hospitalization data were compared be-
tween the group given placebo in the original RCT (n[ 159) and those given rifaximin (n[ 140).RESULTS: In the all-rifaximinpopulation, themedianexposure to rifaximinwas427.0 days (range, 2–1427d),
with 510.5 person-years of exposure. The proﬁle and rate of adverse events with long-term
rifaximin treatment were similar to those of the original RCT. There was no increase in the rate
of infections, including with Clostridium difﬁcile, or development of bacterial antibiotic resistance.
Rates of hospitalizations with long-term rifaximin administration remained low: the HE-related
hospitalization rate, normalized for exposure (0.21; all-rifaximin population), was similar to that
of the rifaximin group in the original RCT (0.30), and lower than that for the placebo group (0.72).CONCLUSIONS: Long-term treatment (‡24 mo) with rifaximin (550 mg, twice daily) appears to provide a
continued reduction in the rate of HE-related and all-cause hospitalization, without an
increased rate of adverse events. ClinicalTrials.gov number: NCT00686920.Keywords: Xifaxan; Cirrhosis; Chronic Liver Disease; Antimicrobial Agent.Abbreviations used in this paper: AE, adverse event; HE, hepatic
encephalopathy; OLM, open-label maintenance study; PYE, person-years
of exposure; RCT, randomized controlled trial.
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Open access under CC BY-NC-ND license.Hepatic encephalopathy (HE) is a serious andpotentially progressive neurologic syndrome in
patients with cirrhosis. The neuropsychiatric symptoms
and neuromuscular dysfunction associated with HE
signiﬁcantly contribute to the clinical and socioeconomic
burden of chronic liver disease for patients and their
caregivers.1,2 HE frequently results in hospitalizations3
and is associated with decreased survival in patients
with cirrhosis.4,5 Prevention of HE episodes may improve
outcomes for patients while awaiting transplantation and
improve post-transplant function.4,5 A long-term thera-
peutic intervention to prevent recurrent HE is needed to
decrease health care burden, improve quality of life, and
improve outcomes for chronically ill patients.
Historically, lactulose and lactitol (available outside of
the United States), and antibiotics have been used asshort-term overt HE treatments.6,7 The presumed
mechanism of action is a reduction in the burden of
neurotoxins derived from both intestinal enterocyte
metabolism (via glutaminase) and gut bacterial meta-
bolism that may contribute to altered mental status;
these toxins accumulate as a result of liver dysfunction
and portosystemic shunting in patients with cirrhosis
and portal hypertension.8 Lactulose therapy can prevent
recurrent HE9; however, long-term use is limited by
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adherence to therapy.10
Rifaximin (Xifaxan; Salix Pharmaceuticals, Inc, Raleigh,
NC) is an oral antimicrobial agent with broad-spectrum
activity that is gut-selective and nonsystemic.11 Rifax-
imin appears to have a low level of selection for resistant
bacterial mutants12 and may not confer the same risks as
those associated with systemic antibiotics. In a random-
ized, double-blind trial, rifaximin therapy signiﬁcantly
reduced the risk of overt HE recurrence and HE-related
hospitalizations during a 6-month period in patients
with cirrhosis and a recent history of recurrent, overt
HE.13 The safety proﬁle was favorable and indistinguish-
able from that of placebo. Nevertheless, theoretical con-
cerns remain regarding the safety and durability of
treatment response during long-term antibiotic use.
The objectives of this open-label study were to
examine the effect of long-term (24 mo) rifaximin
administration on safety, survival, underlying disease,
and rate of hospitalizations in patients with cirrhosis and
recurrent HE.
Methods
Patients
Males and females 18 years of age and older were
eligible if they had a history of overt HE episodes with
documented severity of Conn score of 2 or higher within
12 months before screening, and a Conn score of 2 or less
at enrollment. Patients from a previous randomized
controlled trial (RCT) (ClinicalTrials.gov number:
NCT00298038) were permitted to enroll. Exclusion
criteria included history of allergy to rifampin or rifax-
imin, renal insufﬁciency (serum creatinine level,>2.0mg/
dL), severe anemia (hemoglobin level,<8 g/dL), clinically
signiﬁcant hypovolemia or any electrolyte abnormality
that could affect mental function (eg, serum sodium level,
<125 mEq/L; serum calcium level, >10 mg/dL), severe
hypokalemia (serum potassium level, <2.5 mEq/L), in-
testinal obstruction, active inﬂammatory bowel disease,
diagnosis of human immunodeﬁciency virus, history of
active tuberculosis, or current spontaneous bacterial
peritonitis. The study protocol and the informed consent
form were approved by the institutional review boards of
each center. The trial complied with the Declaration of
Helsinki. All enrolled patients or their legally authorized
representatives provided informed consent. Patients
were enrolled from March 2007 to December 2010.
Study Design, Intervention, and Assessments
This study was a phase 3, multicenter, open-label
maintenance study (OLM) (ClinicalTrials.gov number:
NCT00686920) evaluating oral rifaximin 550 mg admin-
istered twice daily for 24 months or more. Concomitant
therapy with lactulose was optional. Clinic visits occurredat 1 and 3 months, and then every 3 months until the end
of treatment, followed by a 2-week posttreatment clinic
visit. Patients also were monitored by telephone 2 weeks
after beginning rifaximin, and then every 6weeks after the
third month until the end of treatment.
The primary objective was to evaluate the long-term
safety of rifaximin 550 mg twice daily. Adverse events
(AEs) were assessed during each clinic visit and tele-
phone interview, vital sign measurements, hematology,
blood chemistry, urinalysis, and coagulation tests were
conducted during each clinic visit, and a physical exam-
ination was conducted during the end-of-treatment visit
and during clinic visits as needed to evaluate patient
symptoms. Data on infections were captured from the AE
database. Data on Clostridium difﬁcile infections were
investigated further to evaluate the clinical context, na-
ture, and outcome of the infection. Data on hospitaliza-
tions were collected prospectively as part of the primary
objective to analyze safety. Hospitalization data were
investigated further and compared post hoc to assess the
rate of HE-related and all-cause hospitalizations. Overall,
the inclusion/exclusion criteria and safety evaluations
and deﬁnitions were consistent with those in the RCT
clinical trial,13 with the exception of enrollment of
patients with Conn scores of 2 in the OLM.Statistical Analyses
The planned sample size for the OLM was approxi-
mately 300 patients. All analyses were performed for the
safety population, deﬁned as all patients who received 1
or more doses of study medication and had 1 or more
postbaseline safety assessments.
Data were analyzed for all patients treated with
rifaximin 550 mg twice daily during either the OLM or the
previously published RCT13 (all-rifaximin population) and
for a subset of this population: patients who had received
placebo during the RCT13 and received rifaximin during
the OLM, plus patients who only participated in the OLM
(new-rifaximin population). Differences in demographics
and baseline characteristics were determined using the
Fisher exact test or the t test. Nonstatistical comparisons
to historical data from the placebo control group and
rifaximin group from the previously published RCT13
were included, based on methodology and recommenda-
tions from regulatory guidance and published
literature.14–16 This historical RCT and current OLM
included similar enrollment criteria and were supported
by the same organization and investigators. In addition,
demographic and baseline characteristics of the historical
placebo and rifaximin groups were similar to those for the
OLM population, and many of the patients in the placebo
arm of the RCT continued in the OLM.
All continuous and categoric variables were sum-
marized using descriptive statistics. Adherence was
determined at each clinic visit and was calculated as fol-
lows: ([number of tablets dispensed – number of tablets
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tablets that should have been taken daily])  100. The
person-years of exposure (PYE) were calculated as fol-
lows: (total exposure in days O 365.25), and AE rates
were calculated as follows: (number of patientsO PYE), in
which PYE reﬂected exposure up until the AE occurrence
and therefore may have differed from the PYE for the
entire patient group; and the rate of hospitalization events
was calculated as follows: (number of events O PYE),
where PYE reﬂected exposure up until the time the event
occurred.
All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.
Results
Patient Population
Of the 392 patients in the integrated all-rifaximin
population, 83.7% (n ¼ 328) were from the United
States or Canada, and 16.3% (n ¼ 64) were from Russia.
Of the 392 patients (Supplementary Figure 1), 322 were
enrolled in the OLM (70 were treated with rifaximin
during the RCT, 82 were treated with placebo during the
RCT, and 170 were new patients [new-rifaximin popu-
lation, n ¼ 252]). Reasons for discontinuation from the
RCT have been described by Bass et al13 and reasons for
OLM discontinuation are described in Supplementary
Figure 1. Overall demographics, liver disease history,
and HE severity (baseline Conn score and asterixis
grade) were similar among the all-rifaximin, new-rifax-
imin, and historical-rifaximin populations, with generally
no signiﬁcant differences among these groups vs his-
torical placebo (Table 1).13 With regard to the historical
placebo and rifaximin populations, 69.8% and 69.3% of
patients, respectively, had a history of 2 HE episodes in
the previous 6 months, with the remaining patients
having more than 2 HE episodes. During the OLM, 71.4%
of patients in the new-rifaximin population had 2 or
more HE episodes during the previous 12 months. The
median exposure was 427.0 days (range, 2–1427 d; PYE,
510.5) for the all-rifaximin population and 475.5 days
(range, 2–1147 d; PYE, 342.3) for the new-rifaximin
population. Of the 322 patients in the OLM, 92.2%
were 80% or more adherent to treatment.Safety
Adverse events. The summary of AEs (Table 2) and
cirrhosis complication AEs (Table 3) suggest that AE rates
during long-term rifaximin treatment did not increase
compared with historical rates observed for rifaximin or
placebo groups over 6 months. The event rate for serious
AEs per PYE in all-rifaximin patients (0.48) was lower
than in the historical placebo group (1.37). In addition,
results for the new-rifaximin population were similar to
those for the all-rifaximin population.Adverse events involving cirrhosis complications. Most
AEs observed in all groups were related to underlying
liver disease, consistent with a population with cirrhosis.
Infection event rates per PYE for all-rifaximin patients
(0.73) were lower than those observed in the historical-
rifaximin (1.12) and placebo groups (1.33) (Table 3), and
the use of antibiotics (Supplementary Figure 2) did not
generally increase during the long term. Six rifaximin-
treated patients (2 in the RCT and 4 in the OLM) had
C difﬁcile infections (event rate, 0.012); the rates of
C difﬁcile occurrence remained stable with long-term
rifaximin treatment. In addition, all 6 patients had mul-
tiple risk factors for C difﬁcile infection (Supplementary
Table 1). The rates of occurrence of other complica-
tions of cirrhosis, including ascites and edema, variceal
bleeding, anemia, or prolongation of coagulation tests,
did not change appreciably with long-term use of rifax-
imin and appeared similar to rates noted in the historical
placebo group (Table 3).
Among the 392 patients in the all-rifaximin popula-
tion, 352 (89.8%) received concomitant lactulose (range,
15–300 mL/d) and 40 (10.2%) received rifaximin alone.
PYE for rifaximin was 452.9 in the rifaximin-plus-
lactulose group and 57.6 in the rifaximin-alone group.
The incidence of gastrointestinal-related AEs was
signiﬁcantly higher in patients treated with rifaximin
plus lactulose compared with rifaximin alone (69.6% vs
47.5%; P < .001) (Table 4), including the incidences of
nausea and abdominal pain.
Survival. In the all-rifaximin population, 76 patients
died (8 deaths occurred 30 days after the last dose of
study drug). The majority of the 76 deaths were attrib-
uted to liver disease complications (56.6% [n ¼ 43]; with
the majority from liver failure); 19.7% (n ¼ 15) were
attributed to cardiac causes, and 10.5% (n ¼ 8) were
attributed to infection (pneumonia or sepsis). No deaths
were attributed to rifaximin treatment. The mortality
rate (deaths O PYE) for the all-rifaximin population
(0.15) was similar to the rate reported for the historical
placebo group (0.24), and causes of death in the OLM
were consistent with previous reports in the RCT.13
Changes in underlying liver disease. There was also no
apparent difference in the rate of change of Model for
End-Stage Liver Disease scores among the all-rifaximin
population (0.004) and the historical rifaximin (0.006)
and placebo groups (0.005).17
All-Cause and Hepatic
Encephalopathy–Related Hospitalizations
The rates of HE-related hospitalizations in the
all-rifaximin (109 HE-related hospitalizations/510.5
PYE ¼ 0.21 events/PYE) and new-rifaximin (79
HE-related hospitalizations/342.3 PYE ¼ 0.23 events/
PYE) populations, normalized for exposure, were similar
to the rate observed in the historical rifaximin group
(15 HE-related hospitalizations/50.0 PYE ¼ 0.30 events/
PYE), and lower than the rate observed in the historical
Table 1. Demographics, Baseline Characteristics, and Duration of Exposure
Characteristic
Historical
placebo
(n ¼ 159)13
Historical
rifaximin
(n ¼ 140)13
P value vs
historical
placebo
New
rifaximin
(n ¼ 252)
P value vs
historical
placebo
All rifaximin
(N ¼ 392)
P value vs
historical
placebo
Age, y, mean (SD) 56.8 (9.18) 55.5 (9.57) .22 57.5 (8.93) .47 56.8 (9.21) .95
<65 y 128 (80.50) 113 (80.71) 1.0 197 (78.17) .62 310 (79.08) .82
Sex, n (%)
Male 107 (67.30) 75 (53.57) .02 158 (62.70) .40 233 (59.44) .10
Female 52 (32.70) 65 (46.43) 94 (37.30) 159 (40.56)
Race, n (%)
White 139 (87.42) 118 (84.29) 233 (92.46) 351 (89.54)
Black 5 (3.14) 7 (5.00) .51 10 (3.97) .12 17 (4.34) .46
Other/missing 15 (9.43) 15 (10.71) 9 (3.57) 24 (6.12)
Duration of current remission,
d, mean (SD)
73.1 (51.33) 68.8 (47.68) .45 111.1 (108.63) <.0001 95.9 (93.73) .004
Time since diagnosis of liver
disease, mo, mean (SD)
60.51 (64.89) 51.22 (49.17) .17 74.91 (83.49) .07 66.45 (73.92) .38
Time since diagnosis of HE,
mo, mean (SD)
21.85 (26.41) 20.84 (23.13) .73 20.02 (25.26) .48 20.31 (24.50) .52
MELD score, mean (SD) 12.7 (3.94) 13.1 (3.64) .39 12.6 (4.11) .82 12.8 (3.95) .84
MELD score category, n (%)a,b
10 48 (30.19) 34 (24.29) 88 (34.92) 122 (31.12)
11–18 96 (60.38) 94 (67.14) .45c 137 (54.37) .74c 231 (58.93) .53c
19–24 14 (8.81) 12 (8.57) 23 (9.13) 35 (8.93)
Conn score, n (%)
0 107 (67.30) 93 (66.43) 157 (62.30) 250 (63.78)
1 52 (32.70) 47 (33.57) .90 83 (32.94) .34d 130 (33.16) .49d
2 0 0 12 (4.76) 12 (3.06)
Asterixis grade, n (%)
0 108 (67.92) 96 (68.57) 172 (68.25) 268 (68.37)
1 45 (28.30) 41 (29.29) 1.00 64 (25.40) 1.00d 105 (26.79) .92d
2 6 (3.77) 3 (2.14) 16 (6.35) 19 (4.85)
Renal impairment (serum
creatinine), n (%)e
1.5 ULN 3 (1.89) 4 (2.86) 5 (1.98) 9 (2.30)
1.5 ULN 156 (98.11) 136 (97.14) .71 245 (97.22) 1.00 381 (97.19) 1.00
MELD, Model for End-Stage Liver Disease; ULN, upper limit of normal.
aData missing for 1 patient in historical placebo group.
bData missing for 4 patients in the new- and all-rifaximin groups.
cP value determined for categories 18 and >18.
dP value determined for categories 0 and 1.
eData missing for 2 patients in the new- and all-rifaximin groups.
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PYE ¼ 0.72 events/PYE; Figure 1). In addition, the rates
of all-cause hospitalizations, normalized for exposure,
were lower during treatment with rifaximin compared
with the historical placebo group (Figure 1).Table 2. Summary of AEs
Historical placebo
(n ¼ 159)a
Historical
(n ¼ 1
PYE 46.0 50
AEs, number of patients (rateb)
Any AE 127 (2.76) 112 (
Any serious AE 63 (1.37) 51 (
Discontinuations because of AEs 45 (0.98) 30 (
aPrimary results were published previously.13
bAE rates were calculated as follows (number of patientsO PYE), in which PYE reﬂ
from the PYE for the entire patient group.Discussion
This open-label study of long-term (24 mo) rifax-
imin 550 mg administered twice daily included patientsrifaximin
40)a
New-rifaximin population
(n ¼ 252)
All-rifaximin population
(N ¼ 392)
.0 342.3 510.5
2.24) 236 (0.69) 362 (0.71)
1.02) 158 (0.46) 244 (0.48)
0.60) 77 (0.22) 130 (0.25)
ected the exposure up until the AE occurrence and therefore may have differed
Table 3. Complications of Cirrhosis
Historical
placebo
(n ¼ 159)a
Historical
rifaximin
(n ¼ 140)a
All-rifaximin
population
(N ¼ 392)
PYE 46.0 50.0 510.5
Infections (all), n (rateb) 49 (1.33) 46 (1.12) 214 (0.73)
Infections of special
interestc
Cellulitis 3 (0.07) 3 (0.06) 34 (0.07)
C difﬁcile 0 2 (0.04) 6 (0.01)
Peritonitis 6 (0.13) 3 (0.06) 22 (0.04)
Pneumonia 1 (0.02) 4 (0.08) 42 (0.08)
Sepsis/septic shock 5 (0.11) 2 (0.04) 31 (0.06)
Urinary tract/kidney 14 (0.32) 9 (0.19) 83 (0.19)
Complications of portal
hypertension, n (rate)
37 (0.89) 40 (0.96) 195 (0.57)
Acute kidney injury/
hepatorenal syndrome
9 (0.20) 2 (0.04) 74 (0.15)
Ascites and edema 29 (0.69) 34 (0.81) 147 (0.39)
Varices and variceal/GI
bleed
7 (0.15) 6 (0.12) 58 (0.12)
Hematologic complications,
n (rate)
7 (0.16) 13 (0.27) 80 (0.18)
Anemia 6 (0.13) 11 (0.23) 65 (0.14)
Thrombocytopenia/
coagulation
1 (0.02) 3 (0.06) 33 (0.07)
Other, n (rate)
Electrolyte imbalances 3 (0.07) 6 (0.12) 52 (0.11)
Fatigue/sleep disorders 29 (0.70) 26 (0.58) 93 (0.2)
Muscular atrophy 2 (0.04) 0 8 (0.02)
GI, gastrointestinal.
aPrimary results were published previously.13
bAE rates were calculated as follows: (number of patients O PYE), in which
PYE reﬂected the exposure up until the AE occurrence and therefore may have
differed from the PYE for the entire patient group.
cInfections of special interest include infections that commonly occur among
patients with cirrhosis. Patients who had a C difﬁcile infection had recent
clinical histories that included several risk factors for the infection: hepatic
cirrhosis, advanced age, hepatitis C infection, numerous hospitalizations,
multiple courses of antibiotics, and concurrent use of proton pump inhibitors.
Table 4.Gastrointestinal Event Rates for Patients Treated
With Rifaximin With or Without Lactulose
Rifaximin
alone
(n ¼ 40)
Rifaximin þ
lactulose
(n ¼ 352)
PYE 57.6 452.9
Gastrointestinal disorders,
% of patients (ratea)
Overall 47.5 (0.51) 69.6 (1.19)
Abdominal pain 12.5 (0.09) 21.3 (0.20)
Ascites 12.5 (0.09) 17.6 (0.15)
Gastrointestinal bleeding
eventb
10.0 (0.08) 15.9 (0.14)
Nausea 7.5 (0.05) 24.1 (0.23)
Constipation 7.5 (0.06) 12.2 (0.11)
Vomiting 5.0 (0.04) 15.1 (0.13)
Diarrhea 5.0 (0.04) 13.6 (0.12)
Esophageal varices 5.0 (0.04) 5.7 (0.05)
Diverticulum 5.0 (0.04) 1.1 (0.01)
Abdominal distension 2.5 (0.02) 6.3 (0.05)
NOTE. Event rates were reported in 5% of patients in either group.
aAE rates were calculated as follows: (number of patientsO PYE), in which PYE
reﬂected the exposure up until the AE occurrence and therefore may have
differed from the PYE for the entire patient group.
bGastrointestinal bleeding AEs collectively included the following individual
events: gastric hemorrhage, gastritis hemorrhagic, gastroduodenal hemor-
rhage, gastrointestinal hemorrhage, hematochezia, hemorrhoidal hemorrhage,
lower gastrointestinal hemorrhage, melena, esophageal variceal hemorrhage,
rectal hemorrhage, and upper gastrointestinal hemorrhage.
Figure 1. Rates of HE-related and all-cause hospitalizations
for the all-rifaximin and new-rifaximin populations in the OLM
compared with patients receiving historical placebo or rifax-
imin in the 6-month RCT. *P < .0001 vs placebo. Inferential
statistics were not conducted for the all-rifaximin and new-
rifaximin populations.
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and recurrent HE. Rifaximin appeared to provide a
continued decrease in HE-related and all-cause hospi-
talizations, without an increased rate of AEs or change in
survival rates.
The proﬁle and rates of AEs with long-term rifaximin
treatment appeared similar to data previously reported
in the 6-month RCT.13 The lower incidence of
gastrointestinal-related AEs in patients treated with
rifaximin alone is interesting but not unexpected given the
known AE proﬁle of oral disaccharides. However, this
observation may have major treatment implications for
HE because lactulose effectiveness for HE prevention
often is limited by gastrointestinal adverse effects that can
lead to nonadherence to therapy.18–20 Studies comparing
rifaximin plus lactulose vs rifaximin alone are ongoing.
The event rate for serious AEs was low, and there
were no new serious AEs that emerged with long-term
rifaximin treatment. Rifaximin, therefore, appears to be
suitable for maintenance therapy in patients with
cirrhosis. This may be especially important for patientsawaiting liver transplantation, to prevent recurrent overt
HE episodes and potentially permanent neurologic
sequelae.21 In addition, the rates of HE-related and all-
cause hospitalizations, which were considered serious
AEs, appeared to be lower for patients treated with
rifaximin 550 mg twice daily than for the historical pla-
cebo group over 6 months13; this apparent protective
effect was maintained with long-term use.
Patients with cirrhosis have increased susceptibility
to bacterial infections22 that may increase the risk of
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patients receiving long-term therapy with rifaximin
appeared lower than historical placebo and rifaximin
6-month rates. In addition, event rates for the most
common bacterial infections in patients with cirrhosis
(eg, urinary tract infections, upper respiratory tract in-
fections, sepsis, and spontaneous bacterial peritonitis)22
appeared similar or lower than historical placebo and
rifaximin rates. In addition, there was no apparent in-
crease in the rate of infection associated with use of
antibiotics, including C difﬁcile infection, with long-term
rifaximin treatment. Six patients developed C difﬁcile
infection; this rate of C difﬁcile infection (w1%) is
similar to that reported in patients with advanced liver
disease.24 In addition, all 6 patients had multiple risk
factors for C difﬁcile infection, including advanced age,
numerous hospitalizations, multiple courses of antibi-
otics, and concurrent proton pump inhibitor use. All of
the C difﬁcile infections resolved with standard antibiotic
therapy, and 3 patients continued rifaximin treatment
postresolution without recurrence.
Although the current study did not assess microbial
antibiotic resistance, rifaximin appears to have a low level
of selection for resistant bacterial mutants.12 In the
current study, rates of infection and the percentage of
patients treated with antibiotics remained stable or
decreased and was comparable with the historical
6-month RCT rates, indicating no increased risk of
developing infection with long-term exposure to rifax-
imin. In addition, there was no observed rifaximin tachy-
phylaxis, which would have been expected in the face of
substantial bacterial antibiotic resistance. Rifaximin is
associated with lower rates of selection of antimicrobial-
resistant bacterial mutants compared with other antibi-
otics12; additional studies are needed to conﬁrm this
ﬁnding. Furthermore, nonabsorbed antibiotics (rifaximin)
have not been associated with an increased risk of
antibiotic-resistant bacterial infections within 30 days of
exposure in hospitalized patients with cirrhosis (odds
ratio, 0.4; 95% conﬁdence interval, 0.04–2.8).25
No death during the study was attributable to rifax-
imin. In addition, the number of deaths during the study
was lower than expected for this population.26 A 2013
case-controlled study showed an independent association
between rifaximin therapy and greater survival, and a
lower risk of developing variceal bleeding, HE, sponta-
neous bacterial peritonitis, and hepatorenal syndrome.27
Importantly, decreasing hospitalization rates in this high-
risk population may decrease rates of nosocomial in-
fections. The observed mortality during the current study
was consistent with the natural history of advanced liver
disease, and liver disease severity at baseline is likely the
most important factor in determining survival in these
chronically ill patients. As expected for this patient pop-
ulation, most deaths resulted from the progression of
underlying disease and included liver failure and hepatic
neoplasms. This study also examined the effect of chronic
rifaximin use on underlying liver disease, whichremained stable; no adverse effects on cirrhosis pro-
gression or mortality were noted.
The hospitalization and tolerability data reported in
this study have several beneﬁcial implications for treating
patients with cirrhosis. Although this study was not
designed to explore the relative beneﬁts of rifaximin use
for disease maintenance in patients with cirrhosis, these
data, together with results from other studies, present a
favorable proﬁle for long-term treatment with rifaximin
with respect to morbidity andmortality in this chronically
ill population. A study in patients with alcohol-related
decompensated cirrhosis reported that rifaximin treat-
ment reduced endotoxin levels and resulted in signiﬁ-
cantly decreased hepatic venous pressure gradient values,
which decreased the occurrence of complications in
advanced liver disease.28 Intestinal decontamination with
rifaximin has been shown to increase platelet count
signiﬁcantly in thrombocytopenic patients with cirrhosis.
This beneﬁt is thought to be achieved through a
concomitant reduction of endotoxemia.29 Hypothetically,
improvements in platelet counts in patients with throm-
bocytopenia could decrease bleeding risks and compli-
cations of medical procedures, and help stabilize
underlying liver disease. Intestinal decontamination is
also known to increase peripheral blood counts by sup-
pressing endotoxemia and inhibiting the effects of cyto-
kines and nitric oxide on blood counts.30
A potential limitation of this study was that because it
was not a randomized trial with a prospective control
group, there is a potential risk of heterogeneity among
patients when comparing the data from the current study
with historical data. However, regulatory guidance and
published recommendations have provided guidance on
situations in which comparisons to a historical control
may be appropriate (eg, historical controls being part
of recent clinical trials with identical eligibility re-
quirements; the same organization and clinical in-
vestigators that performed the clinical trial performing the
newer trial; and inclusion of patients with similar baseline
characteristics).14–16 As mentioned in the Methods sec-
tion, nonstatistical comparisons with the historical RCT,13
including the placebo arm, were considered methodolog-
ically appropriate in the current study based on multiple
factors, such as similar enrollment criteria and patient
population homogeneity. Nevertheless, corroborating the
current ﬁndings with a long-term, prospectively designed,
controlled study to control for potential population het-
erogeneity and provide statistical analyses is warranted.
Another potential limitation is that 89% of patients took
concomitant lactulose during the study. Although this
study was not powered to assess the effects of rifaximin
alone, it is notable that in the aforementioned RCT,
approximately 91% of patients in both the rifaximin and
placebo groups took concomitant lactulose.13
In conclusion, long-term rifaximin 550 mg twice daily
was well tolerated and appeared to confer a protective
effect against the risk of hospitalizations in patients in
remission from recurrent HE. This open-label study
1396 Mullen et al Clinical Gastroenterology and Hepatology Vol. 12, No. 8was an analysis of rifaximin treatment administered for 24
months or longer, and established the reproducibility and
durability of hospitalization and safety results reported
previously for a 6-month treatment period.13 The safety
proﬁle of long-term rifaximin treatment remained favor-
able, and no negative effects on survival or underlying
cirrhotic diseasewere noted.With these encouraging data,
more attention should bepaid to the population of patients
with cirrhosis and history of overt HE in an effort to reduce
HE recurrence and potentially preserve long-term and
post-transplantation cognition in these patients.
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Supplementary
Figure 1. CONSORT ﬂow
diagram. aThe integrated
safety population (all-rifax-
imin population, N ¼ 392)
included the new-rifaximin
population plus all patients
who received rifaximin
during the RCT regardless
of enrollment into the OLM
(gray shaded boxes). CON-
SORT, Consolidated Stan-
dards of Reporting Trials.
Supplementary Figure 2. Antibiotic use time in the all-rifaximin
population.
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Supplementary Table 1. Cases of C difﬁcile Reported During a 6-month Randomized Trial and 24-month, Open-Label Trial of Rifaximin 550 mg Twice Daily
Age, y/sex Diagnosis
Time to onset of
C difﬁcile diagnosis Outcome
Prior or concurrent
antibiotic use PPI Treatment Action with study drug
60/F C difﬁcile colitis, worsening
encephalopathy
17 d Resolved Numerous hospitalizations
during previous 6 mo
involving treatment with
multiple courses of
antibiotics, started
empirically on
piperacillin þ tazobactam
(3375 mg IV every 6 hours)
on day 15
Pantoprazole Metronidazole,
vancomycin
Permanently discontinued at
day 15 because of SAE of
breakthrough HE
51/M C difﬁcile colitis 52 d Resolved Ciproﬂoxacin Pantoprazole Metronidazole Continued on rifaximin and
ciproﬂoxacin 107 d after
C difﬁcile diagnosis, died
study day 159 of
disseminated intravascular
coagulation following
hepatectomy for liver
transplant
53/F End-stage liver disease,
sepsis MRSA,
vancomycin-resistant
enterococcal infection,
C difﬁcile colitis
24 d after discontinuation of
rifaximin (total exposure to
rifaximin, 47 d)
Resolved Ciproﬂoxacin, vancomycin,
daptomycin
Esomeprazole,
lansoprazole
Metronidazole Rifaximin discontinued on day
47 owing to hepatic failure,
C difﬁcile culture negative
on day 81; nonresuscitation
order day 82, died of
multiorgan failure and end-
stage liver disease on day
86
71/F Severe hyponatremia,
hypoglycemia, CHF,
hospital-acquired
pneumonia, C difﬁcile
colitis
20 d after discontinuation of
rifaximin (total exposure to
rifaximin, 106 d)
Resolved Ceftriaxone, levoﬂoxacin,
vancomycin, piperacillin þ
tazobactam
Esomeprazole Metronidazole Withdrew from study because
of AE of genital bumps,
continued on non-study
rifaximin
40/M C difﬁcile toxin (þ), C difﬁcile
colitis
297 d Resolved Nafcillin, levoﬂoxacin, and
cephalexin administered
for cellulitis and
pseudomonal bacteremia
Omeprazole 2 courses of
metronidazole
Continued on rifaximin
67/F End-stage liver disease,
C difﬁcile colitis
19 d after discontinuation and
18 d after orthotopic liver
transplant (total rifaximin
exposure, 343 d)
Resolved Multiple courses of antibiotics
before C difﬁcile diagnosis,
including ceftriaxone,
ampicillin, ciproﬂoxacin,
and sulfamethoxazole þ
trimethoprim
Pantoprazole Metronidazole Discontinued study because
of liver transplant
CHF, congestive heart failure; IV, intravenously; MRSA, methicillin-resistant Streptococcus aureus; PPI, proton pump inhibitor; SAE, serious adverse event.
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